Payment overview · 2025
General Payments
$388.31
22 reported records · 12 companies
Healthcare provider profile · identity verified
Kirk Elliott
Allopathic & Osteopathic Physicians|Family Medicine · ARNAUDVILLE, LA · NPI 1639104169
Verified facts
What the public records show
CMS Open Payments records show Kirk Elliott received $388.31 in general payments during 2025 across 22 reported records.
Viatris Specialty LLC accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic, Trintellix, Yupelri.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 482 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trintellix by this doctor in 2024.
Viatris Specialty LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported YUPELRI as an associated drug or biological on 26927 records involving 11152 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Yupelri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $89.78 | 23.1% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.85 | 12.8% | 3 | 2025 |
| Cepheid | Unresolved — no canonical attribution shown | $41.72 | 10.7% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $38.32 | 9.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.86 | 8.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.33 | 8.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.35 | 4.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.31 | 4.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.90 | 4.6% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.06 | 4.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.47 | 4.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.36 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $388.31 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $89.78 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.85 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $38.32 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.86 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.33 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.33 | 2 | 2025 |
Source payment records
|
|||||
| GeneXpert Normalized: genexpert |
Device | Cepheid | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 118 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| YUPELRI yupelri |
2025 | Yupelri | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
118 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
482 | 37 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 11 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Viatris Specialty LLC Exact reporting entity; no affiliate inference |
2025 | YUPELRI open payments reported associated product |
CMS Open Payments — General Payments 26927 supporting records · 11152 recipient NPIs · example record 1238463489 |
Yupelri · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 808 | 137 |
| Pantoprazole Sodium | Pantoprazole Sodium | 754 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 721 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 519 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 514 | 76 |
| Eliquis | Apixaban | 487 | 35 |
| Synthroid | Levothyroxine Sodium | 482 | 37 |
| Metformin Hcl | Metformin Hcl | 472 | 91 |
| Gabapentin | Gabapentin | 471 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 440 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 413 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 402 | 58 |
| Potassium Chloride | Potassium Chloride | 355 | 51 |
| Meloxicam | Meloxicam | 336 | 84 |
| Glipizide Er | Glipizide | 318 | 61 |
| Lisinopril | Lisinopril | 317 | 55 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 304 | 63 |
| Furosemide | Furosemide | 291 | 58 |
| Omeprazole | Omeprazole | 290 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 276 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 266 | 93 |
| Finasteride | Finasteride | 246 | 43 |
| Celecoxib | Celecoxib | 236 | 40 |
| Carvedilol | Carvedilol | 230 | 33 |
| Tramadol Hcl | Tramadol Hcl | 217 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 214 | 36 |
| Sertraline Hcl | Sertraline Hcl | 213 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 208 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 207 | 30 |
| Trazodone Hcl | Trazodone Hcl | 201 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 190 | 34 |
| Memantine Hcl | Memantine Hcl | 188 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 185 | 48 |
| Pioglitazone Hcl | Pioglitazone Hcl | 181 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 177 | 25 |
| Losartan Potassium | Losartan Potassium | 177 | 28 |
| Buspirone Hcl | Buspirone Hcl | 175 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 69 |
| Famotidine | Famotidine | 170 | 26 |
| Budesonide | Budesonide | 169 | 23 |
| Montelukast Sodium | Montelukast Sodium | 160 | 30 |
| Alendronate Sodium | Alendronate Sodium | 154 | 16 |
| Donepezil Hcl | Donepezil Hcl | 152 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 21 |
| Mirtazapine | Mirtazapine | 146 | 14 |
| Valsartan | Valsartan | 146 | 28 |
| Allopurinol | Allopurinol | 139 | 24 |
| Arformoterol Tartrate | Arformoterol Tartrate | 136 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 134 | 46 |
| Pregabalin | Pregabalin | 131 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 124 | 16 |
| Fenofibrate | Fenofibrate | 121 | 25 |
| Linzess | Linaclotide | 118 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 117 | 21 |
| Xarelto | Rivaroxaban | 112 | suppressed |
| Prednisone | Prednisone | 108 | 52 |
| Benazepril Hcl | Benazepril Hcl | 107 | 20 |
| Baclofen | Baclofen | 105 | 13 |
| Azelastine Hcl | Azelastine Hcl | 104 | 49 |
| Januvia | Sitagliptin Phosphate | 102 | 11 |
| Jardiance | Empagliflozin | 97 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 93 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 92 | 11 |
| Clonazepam | Clonazepam | 91 | 14 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 85 | suppressed |
| Simvastatin | Simvastatin | 80 | 12 |
| Alprazolam | Alprazolam | 78 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 76 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 70 | suppressed |
| Ozempic | Semaglutide | 65 | 11 |
| Entresto | Sacubitril/Valsartan | 64 | suppressed |
| Novolin R | Insulin Regular, Human | 64 | 12 |
| Risperidone | Risperidone | 64 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 63 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 61 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 61 | suppressed |
| Estradiol | Estradiol | 60 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 60 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 59 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 16 |
| Divalproex Sodium | Divalproex Sodium | 58 | suppressed |
| Ezetimibe | Ezetimibe | 57 | 11 |
| Digoxin | Digoxin | 56 | suppressed |
| Latanoprost | Latanoprost | 56 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 55 | suppressed |
| Lovastatin | Lovastatin | 54 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 53 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 52 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 45 |
| Vraylar | Cariprazine Hcl | 52 | suppressed |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 50 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 50 | suppressed |
| Ibu | Ibuprofen | 49 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 11 |
| Yupelri | Revefenacin | 47 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | suppressed |
| Methylprednisolone | Methylprednisolone | 41 | 31 |
| Trintellix | Vortioxetine Hydrobromide | 41 | suppressed |
| Levofloxacin | Levofloxacin | 40 | 37 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 16 |
| Mupirocin | Mupirocin | 37 | 33 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Methimazole | Methimazole | 36 | suppressed |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 35 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 32 |
| Divalproex Sodium Er | Divalproex Sodium | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | suppressed |
| Movantik | Naloxegol Oxalate | 34 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 28 |
| Lorazepam | Lorazepam | 33 | suppressed |
| Methotrexate | Methotrexate Sodium | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Lactulose | Lactulose | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Cefdinir | Cefdinir | 31 | 30 |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 30 | suppressed |
| Febuxostat | Febuxostat | 29 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | 20 |
| Spironolactone | Spironolactone | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Symproic | Naldemedine Tosylate | 27 | suppressed |
| Rexulti | Brexpiprazole | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 21 |
| Clonidine | Clonidine | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | 12 |
| Rytary | Carbidopa/Levodopa | 23 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 23 | suppressed |
| Alphagan P | Brimonidine Tartrate | 22 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 22 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 22 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Zonisamide | Zonisamide | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 18 | 13 |
| Naproxen | Naproxen | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Nystatin | Nystatin | 16 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Xcopri | Cenobamate | 16 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 15 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 12 |
| Topiramate | Topiramate | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nisoldipine | Nisoldipine | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $388.31 · 22 records | Viatris Specialty LLC | AIRSUPRA, Cologuard Collection Kit, GeneXpert, IBSRELA, LINZESS, MOUNJARO, OTEZLA, Ohtuvayre, Ozempic, REPATHA, Rybelsus, TRINTELLIX, XIFAXAN, YUPELRI | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error